UPDATE 1-Bristol-Myers profit tops Street view, raises full-year forecast

Bristol-Myers Squibb Co on Thursday reported better-than-expected second quarter earnings and raised its full-year forecast on strong sales of its blockbuster cancer drug Opdivo and blood thinner Eliquis.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.